European Medicines Agency grants lacutamab Priority Medicines (PRIME) designation for the treatment of relapsed or refractory Sézary Syndrome

Lacutamab is a first-in-class anti-KIR3DL2 humanised cytotoxicity-inducing antibody. The designation is based on safety and efficacy data from a Phase 1 dose escalation and expansion trial, and supported by safety data from the ongoing Phase 2 TELLOMAK clinical trial.

Source:

Biospace Inc.